A SYSTEMATIC REVIEW OF GUIDELINES FOR MANAGING RHEUMATOID ARTHRITIS by Mian, Aneela et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s41927-019-0090-7
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Mian, A., Ibrahim, F., & Scott, D. L. (2019). A SYSTEMATIC REVIEW OF GUIDELINES FOR MANAGING
RHEUMATOID ARTHRITIS. BMC Rheumatology, 3, [42]. https://doi.org/10.1186/s41927-019-0090-7
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
A SYSTEMATIC REVIEW OF GUIDELINES FOR MANAGING 
RHEUMATOID ARTHRITIS 
 
Aneela Mian 
Fowzia Ibrahim 
David L Scott 
 
 
Address 
Academic Rheumatology 
Department of Inflammation Biology 
School of Immunology And Microbial Sciences 
King’s College London 
Weston Education Centre 
Denmark Hill 
London SE5 9RT 
 
Email Addresses 
Aneela Mian: aneela.mian@nhs.net 
Fowzia Ibrahim 
David L Scott: d.scott1@nhs.net 
 
Corresponding author 
Aneela.mian@nhs.net 
  
2 
 
ABSTRACT 
 
Background 
We systematically reviewed current guidelines for managing rheumatoid arthritis (RA) 
to evaluate their range and nature, assess variations in their recommendations and 
highlight divergence in their perspectives. 
 
Methods 
We searched Medline and Embase databases using the terms ‘clinical practice 
guidelines’ and ‘rheumatoid arthritis’ from January 2000 to January 2017 together with 
publications of national and international bodies. We included guidelines providing 
recommendations on general RA management spanning a range of treatments and 
published in English. We undertook narrative assessments due to the heterogeneity of 
the guidelines.  
 
Results 
We identified 529 articles; 22 met our inclusion criteria. They were primarily developed 
by rheumatologists with variable involvement of patient and other experts. Three dealt 
with early RA, one established RA and 18 all patients. Most guidelines recommend 
regular assessments based on the Outcome Measures in Rheumatology core dataset; 18 
recommended the disease activity score for 28 joints. Twenty recommended targeting 
remission; 16 suggested low disease activity as alternative. All guidelines recommend 
treating active RA; 13 made recommendations for moderate disease. The 21 guidelines 
considering early RA all recommended starting disease modifying drugs (DMARDs) 
as soon as possible; methotrexate was recommended for most patients. 19 
recommended combination DMARDs when patients failed to respond fully to 
monotherapy and biologics were not necessarily indicated. 20 made recommendations 
about biologics invariably suggesting their use after failing conventional DMARDs, 
particularly methotrexate. Most did not make specific recommendations about using 
one class of biologics preferentially. Eight recommended tapering biologics when 
patients achieved sustained good responses.  
 
Conclusions 
Five general principles transcend most guidelines: DMARDs should be started as soon 
as possible after the diagnosis; methotrexate is the best initial treatment; disease activity 
should be regularly monitored; give biologics to patients with persistently active 
disease who have already received methotrexate; remission or low disease activity are 
the preferred treatment target. 
 
KEY WORDS 
Rheumatoid Arthritis 
Systematic Review 
Management Guidelines 
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BACKGROUND 
Guidelines for the management of rheumatoid arthritis (RA) produced by expert groups 
based on assessments of the research evidence have been produced for over 25 years 
[1-4]. They provide explicit recommendations to influence practice through a formal 
process of disseminating advice on effective management. Guidelines can help 
minimise unnecessary care. Many guidelines for managing RA have been published 
over recent years; many of them have been updated to take into account new treatments 
and novel research evidence about existing treatments. 
 
The existence of multiple guidelines raises several questions. First, as they have all had 
access to the same research data, albeit at different time-points, are there 
recommendations similar or are there substantial differences between them? Second, 
why are there different guidelines dealing with the same issue – how best to treat RA? 
Thirdly, what is the impact of these guidelines on clinical practice? Finally, what 
guidelines will be needed in future years? 
 
We have systematically reviewed current RA guidelines.  Our overall aims were to 
evaluate the range and nature of guidelines currently available, to assess the variations 
in their recommendations about RA management, and highlight any divergence in their 
perspectives. The specific questions we considered were: (a) to examine their 
recommendations about composite assessments of disease activity; (b) to identify their 
management targets with drug therapy; (c) to define the categories of drug treatments 
considered. As a consequence of these assessments we sought to provide insights into 
the value and relevance of different guidelines. 
 
METHODS 
Literature Search 
 We searched Medline and Embase databases using the terms ‘clinical practice 
guidelines’ and ‘rheumatoid arthritis’. We also searched national bodies including the 
Scottish Intercollegiate Guidelines Network (SIGN) and the National Institute For 
Health and Care Excellence and national and international specialist societies including 
the British Society for Rheumatology, the American College of Rheumatology and the 
European League Against Rheumatism. Finally we searched lists of references from 
identified guidelines. 
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Inclusion And Exclusion Criteria 
Our inclusion criteria comprised: (a) publications that identified themselves as 
guidelines; (b) guidelines that provided recommendations on the general management 
of RA; (c) guidelines that included a range of different drug treatments; (d) guidelines 
published from January 2000 to January 2017; (e) guidelines published in English. Our 
exclusion criteria comprised: (a) guidelines and appraisals that dealt with specific areas 
of management, such as safety monitoring of drugs; (b) guidelines or appraisals of 
single drugs or technologies. When there were several versions of guidelines from the 
same organisation, only the latest guideline was included. 
 
Screening And Data extraction 
Two researchers (AM, DLS) independently assessed studies for eligibility and 
extracted data onto a predefined template. The data included: (a) year of publication; 
(b) format (who was involved); (c) quality method followed; (d) systematic review of 
evidence; (e) patient groups considered; (f) area of management included; (g) 
composite activity assessments; (h) prognostic assessments; (i) treatment targets; (j) 
and range of treatments considered. When there were differences between assessors, 
they reviewed the reports together and came to a joint conclusion. 
 
Assessment Of Quality Methods 
We sought evidence that individual guidelines had followed nationally or 
internationally accepted quality methods in their development; we did not assess their 
quality as part of this report. Firstly, we recorded who had been involved in developing 
the guideline, including the involvement of specialists, other experts and patients. 
Secondly we evaluated whether they had used recognised quality methods such as 
Agree and Agree II [5], Adapte [6], Grade [7], and National Institute for Health and 
Clinical Excellence (NICE) [8] methods. Thirdly we sought evidence whether they had 
used systematic reviews of published evidence to develop their recommendations. We 
did not specifically examine the quality of individual guidelines because we anticipated 
this would be highly variable because some guidelines were developed by large 
organisations such as the American College of Rheumatology whilst others were 
developed by smaller groups with far less resources making substantial variations in 
the quality of the guidelines inevitable.  
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Methodological Approaches 
We followed the general PRISMA recommendations [9] and other approaches for 
systematic reviews [10], although none of these specifically deal with reviews of 
guidelines. We also followed methods recommended for reviews of systematic reviews 
[11] and approaches taken in previous systematic reviews of guidelines [12,13]. As 
PRISMA does not specifically include systematic reviews of guidelines we did not pre-
register our protocol; this was omitted in other systematic reviews of guidelines [12]. 
 
Methods Of Analysis 
The guidelines were very heterogeneous in terms of the areas covered, the approaches 
taken in their development and the presentation of their recommendations. 
Consequently we undertook narrative assessments of their recommendations. Initially 
we assessed the areas covered by the guidelines, whether they included statements of 
principles and needs, their intended audiences and their overall structure, including 
whether they dealt with specific questions or recommendations. We then focussed on 
three predefined areas related to our specific aims. These comprised; (a) 
recommendations about composite assessments of disease activity and other 
assessments; (b) management targets with drug therapy including the impact of 
prognostic assessments; (c) and the categories of drug treatments considered. We 
considered this approach would enable us to assess the variations in their 
recommendations about RA management and identify divergences in their 
perspectives. We did not set out to produce any single optimal set of recommendations 
for RA management from our analyses of these guidelines. We considered management 
from the perspective of conventional disease modifying anti-rheumatic drugs 
(DMARDs) like methotrexate, biologic DMARDs like tumour necrosis factor 
inhibitors, Janus Kinase (JAK) inhibitors and glucocorticoids (steroids). 
 
RESULTS 
Guidelines Identified 
We identified 529 potential guidelines articles: 80 were assessed in detail; 22 guidelines 
[14-35] selected because they met our inclusion criteria (Figure 1). These included two 
European League Against Rheumatism (EULAR) guidelines, which provided general 
guidance and guidance of treat to target [22,34], and four different guidelines from the 
6 
 
United Kingdom [6,7,24,25], which were produced by various groups at different times 
and worked from varying perspectives. 
 
The 59 excluded guidelines articles included 5 superseded guidelines and one 
separately published summary article, 32 guidelines that dealt with single drugs or drug 
classes, 18 that dealt with non-drug treatments and 3 patient-related articles.  
 
Features Of Guidelines 
These are summarised in Table 1. Groups of expert rheumatologists were reported as 
drawing up 21/22 guidelines; the only exception was the British Columbia guidelines, 
which did not specify who was involved in their construction [18]. There were variable 
levels of patient involvement; 12/22 guidelines specified there was patient involvement 
[14-16, 19-24, 31, 34]. There were also variable levels of contributions from other 
experts, such as nurses, other allied health professionals, experts in systematic reviews 
and a range of other areas; such experts were involved in 12/22 guidelines [14, 16, 19-
23, 29-32, 35]. 
 
The guidelines varied substantially in the ways they were constructed. Three guidelines 
[15, 22, 28] used Agree II methods and one guideline [16] the Agree method, two used 
Grade methods [14,30], one guideline [29] used NICE methods and one guideline [21] 
the Adapte method. Although other guidelines did not use any formal guidelines 
methods, in many instances they were intended to amend existing international 
guidelines for local circumstances. 
 
The approaches to assessing clinical research evidence supporting the guidelines also 
varied. The two EULAR guidelines [22,34] commissioned detailed systematic reviews 
which were published separately [36-36]. The American College of Rheumatology 
(ACR) guideline commissioned [14] detailed systematic reviews that were published 
as an appendix. The English (Royal College of Physicians) guideline [29] 
commissioned detailed systematic reviews for each question which were published 
within the guideline itself. Eight other guide guidelines included some systematic 
reviews [15,16,17,21,24,28,30,32,35] within them, including systematically assessing 
other guidelines, and one other guideline formally used existing published systematic 
reviews to assess each question they considered [30]. 
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Two guidelines dealt with early RA under two years duration [16,20] and one under 
five years duration [30]; one guideline dealt with established RA over 2 years [19] 
duration; the other guidelines dealt with all RA patients. 
 
Areas Covered 
All the guidelines dealt with drug treatment, though they did not all cover the same 
aspects of drug therapy. Eleven guidelines also covered diagnosis [16, 18, 23, 25-27, 
29-32] and 13 covered some or many non-drug treatments [16-20, 23, 27, 29-32, 35]. 
Those guidelines which considered non-drug treatments by multidisciplinary teams 
outlined a range of supportive treatment options. Some of these guidelines, such as the 
Spanish guidelines [32], provided extensive details about these non-drug treatments. 
Others, such as the Scottish guidelines [30], give more general recommendations 
 
Statements Of Principles And Needs 
Guidelines often included a range of statements of general principles, the specific need 
for the guideline and the audience the guideline was intended to inform. These 
statements were so diverse that it is not possible to provide a succinct summary of them.  
 
The EULAR guidelines [22] provided the most extensive global statements which were 
mainly related to ethical issues and philosophical principles such as the central role of 
patients, the role of specialist rheumatologists and the high costs of the disease burden 
in RA. The ACR guideline [14] had more disease specific general principles and 
included statements about the need for payers not to influence some treatment 
decisions. The English (Royal College of Physicians) [29] guideline was most specific 
about its audience, but it was designed to be part of the government-funded National 
Health Service. Other guidelines, such as the APLAR guideline [15] highlighted the 
diversity of patients managed in the areas they represent and the potential differences 
from Western countries. 
 
Intended Audiences 
Twenty guidelines outlined, to a greater or lesser extent, their intended audience [14-
17, 19-31, 33-35]. All 20 indicated they were mainly aimed at clinicians; the Australian 
(Royal Australian College of General Practitioners) indicated their guidelines [16] were 
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specifically intended for GPs. Other guidelines included broader ranges of medical 
specialists and other health care professionals involved in the management of RA. 
Guidelines were sometimes intended to provide information for a broader range of 
readers: 6 guidelines [19, 20, 21, 23, 29, 34] included a range of administrative staff 
including commissioners and payers of healthcare; 7 guidelines [14, 19, 20, 21, 23, 29, 
34] included patients and in some cases  patient groups. An example of a guideline with 
a broad audience is English (Royal College of Physicians) guidance [29] which spanned 
all healthcare professionals, people with RA and their carers, patient support groups, 
commissioning organisations and service providers. 
 
Structure 
13/22 guidelines dealt with specific questions or recommendations [14, 16, 17 19, 21-
25, 28, 29,34, 35]; the average number was 20 (range 10-37). Some of these guidelines 
had specific structures which were replicated across questions; for example the 
Canadian guideline [21] for each question included the recommendation, the supporting 
evidence and the barriers to implementation. The other 9/22 guidelines focused on 
different themes or areas [15, 18, 20, 26, 27, 30-33] which incorporated a number of 
related issues; the average number was 6 (range 3-12). Some of these guidelines also 
had specific structures replicated across themes; for example the English (Royal 
College of Physicians) guideline [29] had summaries of the evidence, sections from 
evidence to recommendations and then one or more recommendations for each of the 
themes it considered. 
 
Assessments 
18/22 guidelines [14, 15, 17, 21-35] recommend regular assessments using a variety of 
clinical assessments based on the Outcome Measures in Rheumatology (OMERACT) 
core dataset [39] using composite indices. These all recommended using the disease 
activity score for 28 joints (DAS28) [40]. In addition 14 aslo recommended simple 
disease activity index (SDAI) and 13 recommended Clinical Disease Activity Index 
(CDAI) [41]. Two guidelines recommended other assessments – the Patient Activity 
Scale (PAS) [42] and Routine Assessment Of Patient Data Index (RAPID3) [43]. None 
of the guidelines specifically recommended one composite index over another. The 
importance of assessing disability was considered by most guidelines. The 
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recommendations varied more widely on how to do this and 10/22 guidelines 
recommended regularly assessing disability [15,17,21,25-27, 29, 31-33]: 9 of these 
recommended using the Health Assessment Questionnaire (HAQ) [44]; the Canadian 
guidelines did not specifically suggest assessing HAQ regularly [21]. 
 
The importance of frequent assessment is stressed in most guidance. Some guidelines 
gave relatively specific suggestions. For example EULAR guidelines recommend 
assessing patients every one to three months, at least in the early stages of their RA. 
Many guidelines indicated patients should be assessed by rheumatologists at least 
annually. The English (Royal College of Physicians) guideline gives a very specific 
recommendation for annual review. The ACR guideline recommended annual 
assessments of function.  
 
Remission And Other Targets 
Twenty guidelines recommended remission as a treatment target and 16 guidelines 
recommended using low disease activity as an alternative target (Table 3). Two 
guidelines recommend aiming to suppress inflammation: the British Columbia 
guideline [18] concluded that the objective of treatment is to “suppress all 
inflammation”, implying this is joint inflammation; the British Society For 
Rheumatology established RA guideline [19] recommended “suppressing 
inflammation” indicating this was to limit disease progression. 
 
Remission was defined in various ways, in keeping with current international criteria 
[45]. DAS28-defined remission was recommended in 13 guidelines, SDAI in 9, CDAI 
in 7 and Boolean in 6. There were 6 guidelines which did not give any criteria for 
assessing the presence of remission. In addition many guidelines emphasised the 
importance of minimising disability, minimising progressive joint damage and 
maximising quality of life, though these were less explicit management goals. 
 
All guidelines recommend treating active RA. There was less unanimity about treating 
moderately active disease. Thirteen guidelines made specific recommendations about 
treating moderate disease. Four guidelines gave implied guidance about treating 
moderate disease in that they indicated what treatment policies were needed until 
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patients achieved remission. Five guidelines made no recommendations about treating 
moderate disease.  
 
Prognostic Assessments To Guide Treatment Decisions 
Sixteen guidelines specifically included assessments of prognostic factors to help guide 
management decisions about treatments [15-18, 21-28, 31-33, 35]. All these 16 
guidelines recommended using anti-citrullinated protein antibodies (ACPA); 14 
guidelines recommended using rheumatoid factor (RF) [15-17, 21-28, 31-33]; 15 
guidelines recommended using x-ray erosion [15-16, 21-27, 31-33,35]; and 9 
guidelines recommended using high disability or extra-articular disease [21, 25-28, 31-
33, 35]. These recommendations are summarised in Table 2. The guidelines including 
prognostic assessments all recommended considering more intensive treatment with 
conventional DMARDs and biologic DMARDs in those patients with poor prognostic 
features. They gave variable details of exactly how this should be achieved. 
 
Initial Conventional DMARD Recommendations 
Twenty one guidelines dealt with the management of early RA; all of these 
recommended starting conventional DMARDs as soon as possible after diagnosis. 
Methotrexate, which is often described as the “anchor” drug for RA, was recommended 
for most patients in 19/22 guidelines [14-17, 20-29, 31-35] (Table 4). In 13/22 
guidelines there was consideration of the relative benefits and risks of oral and 
subcutaneous methotrexate [14, 17, 20-24, 27, 29, 31-33, 35]; however, the approach 
taken to this issue varied considerably and there was no obvious consensus across 
guidelines about when best to use parenteral methotrexate.  
 
When there are contraindications to methotrexate or if there are clinically significant 
adverse events to methotrexate all 19 guidelines that suggested methotrexate as initial 
treatment recommend considering alternative conventional DMARDs. Sulfasalzine, 
leflunomide and hydroxychloroquine were all considered potentially appropriate; there 
was no consistent pattern in these recommendations. Other rarely used conventional 
DMARDs, such as azathioprine, though not excluded were not specifically 
recommended. 
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Three guidelines considered DMARDs generically without giving recommendations 
about which drugs to use; these were the British Guidelines for established [19] and 
early RA [20] and the EULAR treat to target guidance [34]. These three guidelines 
focussed on the overall strategy for managing RA rather than the best individual 
treatment options and so consequently did not provide recommendations about specific 
drugs. 
 
The way individual guidelines outlined the initial treatment for RA varied considerably. 
EULAR guidelines recommend that methotrexate should be part of the first treatment 
strategy. ACR guidelines recommend that DMARD monotherapy is generally more 
acceptable and better tolerated than combination DMARD therapy and that 
methotrexate should be the preferred initial DMARD for most early RA patients. 
Canadian guidelines recommend that initial combination therapy with traditional 
DMARD should be considered, particularly in patients with poor prognostic features, 
moderate-high disease activity and in patients with recent-onset disease. English (Royal 
College of Physicians) guidelines recommended that in people whose RA is active, 
patients should be offered a combination of DMARDs (including methotrexate, at least 
one other DMARD, plus short term glucocorticoids) as first-line treatment. 
 
Combinations Of Conventional DMARDs 
Twenty guidelines considered the use of combinations of conventional DMARDs; 19 
of these guidelines recommended using them in some patients [14-18, 20-21, 23-33, 
35]. They were recommended when patients failed to respond fully to DMARD 
monotherapy and that biologics were not necessarily indicated. Specific Combinations 
of conventional DMARDS were recommended by 12/22 guidelines [14,15,17,21,23-
28, 31, 33]: these combinations comprised methotrexate with sulfasalazine and 
hydroxychloroquine or methotrexate with leflunomide in 9 guidelines; 2 guidelines 
omitted leflunomide from combinations [23,33] and one guideline recommended 
chloroquine instead of hydroxychloroquine [31]. One guideline, from England, 
recommended initial combinations of conventional DMARDs [29], though it did not 
specify which drugs to use. 
 
The one exception was the EULAR guidelines which do not specifically recommend 
using them. However, EULAR did not exclude their use, and mention them briefly. The 
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EULAR guidelines also provide an extensive commentary on the divergence of expert 
opinion on this issue, highlighting potential toxicities and difficulties dissociating the 
impact of methotrexate, short-term glucocorticoids (steroids) and other conventional 
DMARDs in combinations.  
 
Janus Kinase Inhibitors  
Only 4 guidelines consider the use of Janus Kinase inhibitors; this mainly reflects 
whether they were developed after these drugs became available. Those guidelines that 
consider them recommend their use as an alternative to biologics in some patients with 
established RA. They are usually recommended to be used in combination with 
methotrexate. 
 
Glucocorticoids (Steroids) 
Twenty guidelines recommended using glucocorticoids in some RA patients; these 
were usually patients with early RA who were starting DMARD treatment. In the main 
only short-term courses of low dose glucocorticoids (steroids) were recommended. The 
EULAR treat to target guideline implied glucocorticoids (steroids) should be used 
within the treatment strategy in some patients but did give any recommendations about 
specific therapies. The British guidelines for established RA did not consider 
glucocorticoids (steroids). In addition some guidelines gave advice about the role of 
glucocorticoids (steroids) in specific clinical settings, particularly in the management 
of some comorbidities.  
 
Biologic DMARD 
Twenty guidelines made recommendations about using biologics. Three guidelines 
made generic recommendations about biologics and the other 17 that dealt with them 
considered individual biologics and classes of biologics. The 2 guidelines that did not 
were for primary care clinicians who should not usually prescribe these treatments. All 
the guidelines that dealt with biologics recommended their use in patients who had 
failed to respond to conventional DMARDs, particularly methotrexate. They also 
recommended using them in combination with methotrexate whenever possible. Most 
guidelines did not make specific recommendations about using one class of biologics 
preferentially. However, some guidelines such as the Canadian ones, recommend using 
tumour necrosis factor inhibitors as an initial biological treatment. In patients who have 
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continuing disease activity despite biologic treatment or adverse events to biologics 
starting an alternative biologic was recommended. In most instances no particular 
sequences of biologics were recommended in the different guidelines. 
 
Biologic DMARD Tapering 
Eight guidelines recommended considering tapering biologic treatment in patients who 
had achieved sustained good responses and remissions. A further two guidelines 
implied this was appropriate without giving detailed recommendations. 
 
Symptomatic Treatment 
Thirteen guidelines made recommendations about the use of NSAIDs and 12 about 
using analgesics to control symptoms. Those guidelines which consider the use of 
NSAIDs invariably focus on minimising exposure to these treatments. For example the 
Scottish Guidelines suggest using the lowest NSAID dose compatible with symptom 
relief, and indicate that treatment should be reduced and if possible withdrawn as soon 
as possible and that gastro-protection should be included when using them. When 
analgesics such as paracetamol were mentioned for symptom relief though the evidence 
supporting their use is noted to be minimal by current standards. 
 
DISCUSSION 
Our overview of 22 different RA management guidelines shows that several general 
principles transcend the majority of them. Firstly DMARDs should be started as soon 
as possible after the diagnosis has been established. Secondly disease activity should 
be regularly monitored using composite indices such as DAS28, which relates to our 
initial aim which was our initial specific question. Thirdly methotrexate is the best 
initial treatment, and that this can be usefully supplemented with short-term 
glucocorticoid (steroid) therapy. Fourthly biologic DMARDs should be given to 
patients with persistently active disease who have already received methotrexate and, 
in some instances another conventional DMARD. These principles relate to another of 
our specific questions.  Fifthly remission or low disease activity is a suitable target and 
that treatment can be tapered in patients who have achieved sustained remissions. This 
principle relates to our final specific question. We consider that applying these general 
principles to RA management in all clinical settings is likely to achieve good overall 
clinical outcomes. 
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There is considerable uncertainty about the value and place for using combinations of 
conventional DMARDs. The most recent EULAR guidance is particularly uncertain 
about its value. Other guidance including the ACR guidance is more definite it is 
perspective. The reasons for this difference are unclear. In part it may be presentational; 
EULAR guidance does not exclude using such combinations and ACR guidance does 
not explicitly recommend them; consequently much of the apparent difference may 
represent the way in which the information is presented. There has been correspondence 
about this particular aspect of the EULAR guidelines [46,47]. However, the balance of 
opinion in these various guidelines favours the use of combinations of conventional 
DMARDs in some patients. Interestingly, recent guidance from NICE in a multiple 
technology appraisal (a type of assessment we excluded from this systematic review) 
recommended only starting biologics in patients with disease that had not responded to 
intensive therapy with a combination of conventional DMARDs [48]. These 
perspectives were from expert groups who had considered the same evidence in detail 
and they show the divergence of expert views when assessing clinical research findings.  
 
There is also relatively little overall consensus about treating moderately active RA. 
The ACR guidance makes the strongest recommendation on this point. Other guidance 
has either not considered it or may have been published prior to much evidence 
becoming available. Despite the limitations of explicit recommendations, those 
guidelines which consider moderate disease recommend treating it intensively. 
 
The guidelines differ in the formality of their approach and in the extent of systematic 
reviews commissioned specifically for them. The EULAR, ACR and Royal College of 
Physicians guidelines were the most detailed and involved the greatest amount of 
preparatory work including a number of detailed systematic reviews. Specialist 
rheumatologists were involved in almost all guidelines; varying numbers of other 
experts and patients were involved. The impact that these non-rheumatologists would 
be able to make to the guidelines was uncertain. 
 
The limitations of clinical guidelines have been described in detail [49-52]. We do not 
intend to consider the relative strengths and weakness of guidelines in general. 
However, one particular challenge with the current published guidelines is that only 
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8/22 specifically followed a nationally or internationally agreed approach to ensure they 
were of high quality. Future guidelines ought to explicitly adopt one of these quality 
methods. In RA the overall the degree of agreement between the guidelines is striking 
and exceeds the differences between them. As health care is not universally uniform it 
is inevitable national groups would wish to have their own local guidelines, which 
reflect the arrangements of their medical systems. The overall impact of the guidelines 
is difficult to establish. As the various updates of ACR and EULAR guidelines have 
high citation rates on bibliometric systems it seems likely they are used by many groups. 
Some guidelines have immediate practical implications. For example technology 
appraisals by NICE, though outside our remit, have been crucial for ensuring patients 
have access to high cost therapies. It is likely guidelines achieve this goal more globally, 
and the appearance of many guidelines reflects the major changes in drug therapy for 
RA in recent years. 
 
Our own assessment of RA guidelines has its own limitations. Firstly, some of the 
guidelines were developed over 10 years or longer and the older ones cannot have 
included the more recent clinical evidence. Therefore comparisons need to take this into 
account. Secondly, there are different types of guidelines. We have included general 
ones. Many others focus on single drugs or treatment modalities including surgery. It 
is difficult to draw a clear line between which ones to include and which to omit. Not 
all experts would necessarily agree with our approach to inclusion. Thirdly, we have 
only provided a narrative assessment of them. They are too diverse in their approaches 
to allow any synthesis of their various conclusions and recommendations.  Fourthly we 
have focussed on issues in the guidelines we consider to be of most importance. Other 
experts may have considered different aspects of the guidelines in more detail and 
overlooked some of the matters we have dealt with. Finally, systematic reviews of 
guidelines are not one of the current PRISMA extensions [53] though we anticipate 
they will be included in subsequent updates. Consequently we did not register our 
protocol; however, several other recent systematic reviews have evaluated different 
guidelines using similar approaches to our own, such as the report by Jollife et al on 
stroke rehabilitation guidelines [13] Systematic reviews of guidelines differ from both 
scoping [54] and umbrella reviews [55]. 
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Our analysis shows several things. Firstly, the recommendations in the guidelines are 
broadly similar, though they differ in some points of detail; for example the use of 
combinations of conventional DMARDs. Such minor variations most likely reflect the 
challenges in balancing evidence of benefits against evidence of risks. Secondly, 
although guidelines deal with the same issue, they bring together different groups of 
experts and it is likely the production of guidelines enhances clinical practice. 
Consequently multiple guidelines appear to be needed. Thirdly, although it is difficult 
to judge accurately the impact of guidelines on clinical practice, there is evidence that 
RA outcome have improved significantly during the last 10-20 years and in part this is 
likely to reflect the impact of guidelines in improving the quality of clinical practice. 
Finally, as new treatments are introduced, particularly new JAK inhibitors, guidelines 
will need to be continually updated and, potentially produced by different groups. 
 
We anticipate that many of the existing guidelines will be updated in future years. We 
believe it important to do so to maintain their relevance to clinical practice. The 
frequency of review will reflect the timing of new clinical information. Looking back 
at the earliest guidelines from the 1990s [1-3] shows just how much clinical practice 
has changed over the years, indicating the need for guidance to be updated. We consider 
there are two ways in which the process of developing guidelines could be improved. 
Firstly, there guideline development should conform with one of the published quality 
standards; whilst there is no reason to prefer one standard over another, it seems 
worthwhile to adopt one of them. Secondly, guidelines should incorporate divergent 
views, when there is no universally agreed answer. The controversy about the value of 
combinations of conventional DMARDs highlights this issue.  
 
One important role of guidelines is to suggest potential future research questions. Our 
own research in the TITRATE research programme, of which this systematic review in 
a single component, was based on the absence of evidence on the benefits of intensive 
management in moderately active RA [56]. Interestingly, though the clinical research 
evidence has changed little on this aspect of treat to target, current guidelines often 
recommend treating moderately active RA intensively, showing the way in which 
guidelines interpret the evidence in very different ways. 
 
CONCLUSIONS 
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Although a number of differences exist between guidelines, there are some general 
principles. These include starting DMARDs soon after diagnosis; methotrexate should 
be used first line; disease activity should be monitored regularly; biologics therapies 
should be used where there is persistently active disease; and remission or low disease 
activity is the preferred target. 
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Table 1. Features Of Clinical Guidelines Included In Review  
 
Guideline Year Format 
Quality 
Method 
Systematic Review Of 
Evidence 
Patients Areas Covered 
  Specialists 
Other 
Experts 
Patients  In Guideline Separate  Diagnosis Drugs MDT 
1. American [14] 2015 Yes Yes Yes Grade Yes - All - Yes - 
2. APLAR [15] 2015 Yes - Yes Agree II Yes* - All - Yes - 
3. Australian [16] 2009 Yes Yes Yes Agree Yes* - <2 years Yes Yes Yes 
4. Brazilian [17] 2012 Yes - - - Yes - All - Yes Yes 
5. British Columbia [18] 2012 Not Specified - - - All Yes Yes Some 
6. British Society For Rheumatology: Established 
[19] 
2009 Yes Yes Yes - - - >2 years - Yes Yes 
7. British Society For Rheumatology: Early [20] 2010 Yes Yes Yes - - - <2 years Yes Yes Yes 
8. Canadian [21] 2011 Yes Yes Yes Adapte Yes*  All - Yes - 
9. EULAR [22] 2016 Yes Yes Yes Agree II - Yes All - Yes - 
10. French [23] 2014 Yes Yes Yes - - - All Yes Yes Some 
11. German [24] 2013 Yes - Yes - Yes  All  Yes - 
12. Hong Kong [25] 2010 Yes Not Specified - - - All Yes Yes - 
13. Indian [26] 2008 Yes Not Specified - - - All Yes Yes Yes 
14. Latin American [27] 2006 Yes Not Specified - - - All Yes Yes Yes 
15. Mexican [28] 2014 Yes Not Specified Agree II Yes* - All  Yes  
16. England [29] 2009 Yes Yes Yes NICE Yes - All Yes Yes Yes 
17. Scotland [30] 2011 Yes Yes - Grade Yes**  <5 years Yes Yes Yes 
18. South African [31] 2013 Yes Yes Yes - - - All Yes Yes Yes 
19. Spanish [32] 2007 Yes Yes - - Yes  All Yes Yes Yes 
20. Swedish [33] 2011 Yes Not Specified - - - All - Yes - 
21. Treat to Target [34] 2010 Yes - Yes -  Yes All - Yes - 
22. Turkish [35] 2011 Yes Yes - - Yes  All - Yes Yes 
 
* Systematically reviewed other guidelines; ** used existing published systematic reviews. MDT=multidisciplinary team 
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Table 2. Recommended Composite Disease Activity Assessments And Prognostic Assessment To Guide Treatment 
 
Guideline Composite Disease Activity Assessments Prognostic Assessments 
 PAS RAPID3 CDAI SDAI DAS28 RF ACPA 
X-ray 
Erosions 
Poor 
Function 
Extra-Articular 
Disease 
1. American [14] Yes Yes Yes Yes Yes      
2. APLAR [15] - - Yes Yes Yes Yes Yes Yes   
3. Australian [16] - - - - - Yes Yes Yes   
4. Brazilian [17] - - Yes Yes Yes Yes Yes Yes   
5. British Columbia [18] - - - - -  Yes Yes   
6. British Society For Rheumatology: Established [19] - - - - -      
7. British Society For Rheumatology: Early [20] - - - - -      
8. Canadian [21] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
9. EULAR [22]   Yes Yes Yes Yes Yes Yes   
10. French [23]   Yes Yes Yes Yes Yes Yes   
11. German [24] - - - - Yes Yes Yes Yes   
12. Hong Kong [25] - - Yes Yes Yes Yes Yes Yes Yes Yes 
13. Indian [26] - - Yes Yes Yes Yes Yes Yes  Yes 
14. Latin American [27] - - - - Yes Yes Yes Yes Yes Yes 
15. Mexican [28]   Yes Yes Yes Yes Yes   Yes 
16. England [29] - - - - Yes      
17. Scotland [30] - - Yes Yes Yes      
18. South African [31] - - - Yes Yes Yes Yes Yes Yes Yes 
19. Spanish [32] - - Yes Yes Yes Yes Yes Yes Yes Yes 
20. Swedish [33] - - Yes Yes Yes Yes Yes Yes Yes Yes 
21. Treat to Target [34] - - Yes Yes Yes      
22. Turkish [35] - - - - Yes  Yes Yes Yes  
RF=rheumatoid factor; ACPA=anti-citrullinated protein antibody 
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Table 3. Recommended Treatment Targets   
 
Guideline Treatment Target Remission Definitions  
Treat Moderate 
Disease 
 Remission LDA 
Suppress 
Inflammation 
     
1. American [14] Yes Yes - SDAI Boolean   Yes 
2. APLAR [15] Yes Yes - DAS28 SDAI CDAI Boolean Yes 
3. Australian [16] Yes - - - - - - Yes 
4. Brazilian [17] Yes Yes  DAS28 SDAI CDAI - Yes 
5. British Columbia [18] - - Yes - - - - - 
6. British Society For Rheumatology: Established 
[19] 
Yes - Yes - - - - - 
7. British Society For Rheumatology: Early [20] - - - - - - - - 
8. Canadian [21] Yes Yes - DAS28 SDAI CDAI Boolean Yes 
9. EULAR [22] Yes Yes - SDAI Boolean - - Yes* 
10. French [23] Yes Yes - DAS28 SDAI CDAI Boolean Yes 
11. German [24] Yes Yes - DAS28 - - - Yes* 
12. Hong Kong [25] Yes - - DAS28 - - - Yes* 
13. Indian [26] Yes - - - - - - Yes 
14. Latin American [27] Yes Yes - DAS28 - - - - 
15. Mexican [28] Yes Yes - DAS28 - - - Yes 
16. England [29] Yes Yes - DAS28 - - - - 
17. Scotland [30] Yes Yes - DAS28 - - - Yes 
18. South African [31] Yes Yes - SDAI - - - Yes 
19. Spanish [32] Yes Yes - DAS28 CDAI Boolean - Yes* 
20. Swedish [33] Yes Yes - DAS28 SDAI CDAI - Yes 
21. Treat to Target [34] Yes Yes - DAS28 SDAI CDAI Boolean Yes 
22. Turkish [35] Yes Yes - - - - - Yes 
 
*Treatment of moderate RA is implied rather than definitively stated 
LDA=Low Disease Activity 
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Table 4 Drug Treatment Recommendations 
 
Guideline DMARDs Biologics 
Symptomatic 
Treatments 
 MTX Others Combinations 
JAK 
Inhibitors 
Glucoco
rticoids 
(steroids
) 
First Subsequent Tapering NSAIDs Pain 
1. American [14] Yes Yes Yes Yes Yes Yes Yes Yes - - 
2. APLAR [15] Yes Yes Yes Yes Yes Yes Yes Yes Yes - 
3. Australian [16] Yes Yes Yes - Yes Only for specialists Yes Yes 
4. Brazilian [17] Yes Yes Yes - Yes Yes Yes Yes Yes - 
5. British Columbia [18] Yes Yes Yes - Yes Only for specialists Yes Yes 
6. British Society For Rheumatology: Established [19] Generic DMARDs - - - Generic biologics  Yes Yes 
7. British Society For Rheumatology: Early [20] Generic DMARDs Yes - Yes Generic biologics Implied Yes Yes 
8. Canadian [21] Yes Yes Yes - Yes Yes Yes Yes - - 
9. EULAR [22] Yes Yes - Yes Yes Yes Yes Yes - - 
10. French [23] Yes Yes Yes - Yes Yes Yes Yes - - 
11. German [24] Yes Yes Yes - Yes Yes Yes - - - 
12. Hong Kong [25] Yes Yes Yes - Yes Yes Yes - - - 
13. Indian [26] Yes Yes Yes - Yes Yes Yes - Yes Yes 
14. Latin American [27] Yes Yes Yes - Yes Yes Yes - Yes Yes 
15. Mexican [28] Yes Yes Yes Yes Yes Yes Yes - Yes Yes 
16. England [29] Yes Yes Yes - Yes Yes Yes - Yes Yes 
17. Scotland [30] Yes Yes Yes - Yes Yes Yes - Yes Yes 
18. South African [31] Yes Yes Yes - Yes Yes Yes - Yes Yes 
19. Spanish [32] Yes Yes Yes - Yes Yes Yes - Yes Yes 
20. Swedish [33] Yes Yes Yes - Yes Yes Yes Yes - - 
21. Treat to Target [34] Generic DMARD treatments - Yes Generic biologics Implied - - 
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22. Turkish [35] Yes Yes Yes - Yes Yes Yes Yes - - 
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Figure PRISMA 2009 Flow Diagram 
 
 
Records identified through 
database searching 
(n = 523) 
Sc
re
en
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources 
(n = 6) 
Records after duplicates removed 
(n = 529) 
Records screened 
(n = 529) 
Records excluded 
(n = 448) 
Full-text articles assessed 
for eligibility 
(n = 80) 
Full-text articles excluded, with 
reasons 
(n = 59) 
 
Previous guideline/summary (n = 6) 
Single drug/drug type (n = 32) 
Non-drug (n = 18 
Patient-related (n = 3) 
Studies included in 
qualitative synthesis 
(n = 22) 
